CELG News and Press, Celgene Corporation From 11/04/19

The spread on the Bristol-Myers (BMY) and Celgene (CELG) deal has been rapidly closing recently. The gross spread is a negative 1.28%. I've written a ton about this deal in the past, and it is my largest M&A position. The spread is finally getting so tight that you need to ascribe value to...

In a bid to spark inflation by boosting loan activity and business investment, the Federal Reserve lowered its target rate this week by an additional 25 basis points to a range of 1.50% to 1.75%. The lowered rates could make this a good time to buy stocks, but stock picking is more important...

The following slide deck was published by Celgene Corporation in conjunction with their 2019 Q3 earnings Read more ...

Baird's Brian Skorney has downgraded Celgene (NASDAQ: CELG ) to Neutral with a $101 price target citing its  27%  climb this year and the Bristol-Myers deal spread narrowing to $0.66. More news on: Celgene Corporation, Healthcare stocks news, Stocks on the move, Read more ......

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Apple ( AAPL ) looks like a "double-top" formation, fast traders should look to trim some shares Let me first say again that I am a fan of AAPL, I am a fan of CEO Tim Cook. Also, let me say that this is NOT a call for long-term investors or even speculators that wanted to hold AAPL into ...

Celgene (NASDAQ: CELG ): Q3 Non-GAAP EPS of $2.99 beats by $0.28 ; GAAP EPS of $1.50 misses by $0.69 . Revenue of $4.52B (+16.2% Y/Y) beats by $130M . Press Release More news on: Celgene Corporation, Earnings news and commentary, Healthcare stocks news,

- Strong total revenue of $4.5 billion, increased 16% Y/Y driven by volume - INREBIC ® (fedratinib) granted FDA approval in myelofibrosis; EU MAA submission expected by year-end 2019 - Expected Q4 regulatory updates include: Dec. 4, 2019 FDA PDUFA date for luspatercept in t...

Celgene Or Bristol-Myers: Comparing The Two Bristol-Myers Squibb ( BMY ) have successfully offered to acquire Celgene ( CELG ), and the transaction is expected to complete in early January 2020. This means a shareholder in Celgene no longer has an interest in the Celgene busi...

Company Overview Allogene Therapeutics ( ALLO ) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer. Allogene believes that the next revolution in cancer treatment is the development of AlloCAR T therapie...